論文

査読有り 国際誌
2020年6月

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.

Future oncology (London, England)
  • Jean-Pascal Machiels
  • ,
  • Yungan Tao
  • ,
  • Barbara Burtness
  • ,
  • Makoto Tahara
  • ,
  • Lisa Licitra
  • ,
  • Danny Rischin
  • ,
  • John Waldron
  • ,
  • Christian Simon
  • ,
  • Vincent Gregoire
  • ,
  • Kevin Harrington
  • ,
  • Gustavo Vasconcelos Alves
  • ,
  • Iane Pinto Figueiredo Lima
  • ,
  • Yoann Pointreau
  • ,
  • Brett G M Hughes
  • ,
  • Sercan Aksoy
  • ,
  • Marcin Hetnal
  • ,
  • Joy Y Ge
  • ,
  • Holly Brown
  • ,
  • Jonathan Cheng
  • ,
  • Behzad Bidadi
  • ,
  • Lillian L Siu

16
18
開始ページ
1235
終了ページ
1243
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.2217/fon-2020-0184

Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC. Clinical Trial Registration: NCT03040999 (ClinicalTrials.gov).

リンク情報
DOI
https://doi.org/10.2217/fon-2020-0184
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32490686

エクスポート
BibTeX RIS